Background 

When bladder cancer spreads, or becomes “metastatic,” treatment choices after the first round of chemotherapy are very limited. A newer type of treatment called immunotherapy has given patients hope. These treatments, known as checkpoint inhibitors, work by “releasing the brakes” on the immune system so it can fight the cancer. While some patients have seen long-lasting benefits, only a small number actually respond to this therapy. Doctors and researchers want to figure out why this happens and who is most likely to benefit. 

One focus of this study is on a special type of immune cell called regulatory T cells. Normally, these cells act like traffic police, slowing down immune reactions so the body doesn’t attack itself. But in cancer, they can work against patients by protecting tumors from being attacked. Researchers have found these cells inside bladder tumors, and they think that treatments blocking PD-L1—a common type of immunotherapy—may change how these cells behave. 

What This Research Proposes to Address 

This project will look closely at how anti-PD-L1 therapy affects regulatory T cells in patients with bladder cancer. The researchers will study how many of these cells are present, where they are located inside the tumor, and what specific “signals” they are responding to. To do this, they will use new scientific tools and also run a clinical trial. In this trial, patients will receive immunotherapy before having surgery to remove their tumors. This gives the researchers a unique chance to directly examine how the treatment changes the tumor and the immune system. 

Why This Research Is Important 

By learning more about how regulatory T cells respond to immunotherapy, this research could help doctors understand why some patients do well with these treatments and others do not. The findings may lead to new ways of predicting who will benefit from immunotherapy and could even uncover new strategies to improve treatment for bladder cancer patients. 

Final Report Summary

Thanks to funding from BCAN, researchers studied special immune cells called T cells in people with bladder cancer. These cells help the body fight off infections and sometimes cancer, but they can act in different ways. Some T cells, called regulatory T cells, actually slow down the immune system, making it harder to fight the cancer. This study found that these “slowing” cells come in several types and seem to focus on the bladder tumors themselves. 

The researchers also discovered a brand-new kind of T cell that does the opposite—it attacks bladder cancer cells. This cell type, called a CD4 T cell, may even help predict which patients will respond better to a type of immunotherapy called a checkpoint inhibitor. 

By learning how these two very different T cells interact, scientists may be able to design new treatments that block the cells that weaken the immune system and boost the ones that attack cancer. This could lead to stronger and more effective therapies for people with bladder cancer. 

Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., Allaire, K., Burra, A., Sun, Y., Spitzer, M. H., Mangul, S., Porten, S., Meng, M. V., Friedlander, T. W., Ye, C. J., & Fong, L. (2020). Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell, 181(7), 1612-1625.e13. https://doi.org/10.1016/j.cell.2020.05.017

None Reported as of August 2025

NA